Ypsomed opens up new markets
Burgdorf, 10.10.2017, 7.00 am – Following the successful launch of its own insulin pump, the mylife YpsoPump, Ypsomed pursues its continued growth and invests in establishing new subsidiaries throughout Europe. At the same time, the mylife YpsoPump is being launched in further European countries.After founding subsidiaries in Czechia and Australia last year, Ypsomed has set up three further subsidiaries during the past weeks, in Belgium, Spain and Poland. With an overall approximate 600,000 type 1 diabetics, expansion into these three countries is the next step in gaining further market shares in the insulin pump business and in establishing Ypsomed as a worldwide specialist in diabetes. Furthermore, Ypsomed will gain additional sales markets for its own mylife YpsoPump brand of insulin pumps with the new subsidiaries.
The mylife YpsoPump has been launched in several European markets since August of last year and has gained first market shares. "We are very satisfied with the start of the mylife YpsoPump in Europe. Over the past twelve months we have seen that the insulin pump meets the needs of users and can simplify diabetes therapy. We are therefore confident and invest strongly into building up the Diabetes Care Segment", explains Simon Michel, Ypsomed’s CEO.
In October, Ypsomed also launches the mylife YpsoPump in its home market Switzerland. Dr. Sistiana Heidemann, Head of Sales Switzerland, foresees major opportunities for the new insulin pump in Switzerland: "The small, extremely handy insulin pump includes all important functions and excels through particularly easy operation. The mylife YpsoPump dispenses with highly complicated technical details on purpose and thus differs considerably from all other common insulin pump systems. The positive echo we have received from users and the professional diabetes teams reflects the real need for such a pump."
For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG.
Contact:Thomas Kutt
Head of Investor Relations
Ypsomed Holding AG
Phone +41 34 424 35 55
Send emailDownloads: About the Ypsomed GroupThe Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1’400 employees. Additional information is available under
www.ypsomed.com.
